Navigation Links
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
Date:11/25/2008

SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced that data from two ongoing Phase 2 clinical trials of carfilzomib in multiple myeloma will be presented at the upcoming 50th Annual Meeting of the American Society of Hematology (ASH). Carfilzomib is the first in a new class of specific proteasome inhibitors and is currently in multiple clinical trials for hematologic malignancies and solid tumors. This year's ASH conference will be held December 6-9, 2008 at the George Moscone Center in San Francisco, California.

Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York will present initial results from Proteolix's Phase 2 study of carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma during the Novel Therapies for Myeloma and Related Disorders session at 7:00 a.m. on Tuesday, December 9, 2008. This ongoing Phase 2 trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. Data from a second ongoing Phase 2 clinical trial of single-agent carfilzomib in relapsed multiple myeloma patients (stratified by prior therapy with bortezomib) will be presented immediately thereafter at 7:15 a.m. by Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine.

In addition to the oral presentations, the company will have several poster presentations highlighting the results of preclinical studies that further characterize the mechanism and safety profile of carfilzomib. Proteolix will also have a poster presentation on the preclinical pharmacology and characterization of its oral proteasome inhibitor known as PR-047.

A complete list of the company's oral and poster presentations at the ASH meeting follows:

    Oral Presentations -- Tuesday, December 9, 2008
      Session:  Novel Therapies for Myeloma and Related Disorders
      --  7:00 a.m. PST: Initial Results of PX-171-003, An Open-Label,
          Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with
          Relapsed and Refractory Multiple Myeloma (MM) (Abstract #864)
      --  7:15 a.m. PST: Initial Results of PX-171-004, An Open-Label,
          Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with
          Relapsed Myeloma (MM) (Abstract #865)
      Location: Moscone Center, Gateway Ballroom 103-South


    Poster Presentations
    Sunday, December 7, 2008, 6:00 p.m. -- 8:00 p.m. PST
      Session: Molecular Pharmacology, Drug Resistance Poster II
      --  Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and
          Carfilzomib (Abstract #2657)
      Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding
       Therapy Poster II
      --  The Selective Proteasome Inhibitor Carfilzomib is Well Tolerated in
          Experimental Animals with Dose Intensive Administration (Abstract
          #2765)
      Location: Moscone Center Hall A


    Monday, December 8, 2008, 5:30 p.m. -- 7:30 p.m. PST
      Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding
       Therapy Poster III
      --  Induction of Sustained Early G1 Arrest by Selective Inhibition of
          CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by
          Proteasome Inhibitors Carfilzomib and PR-047 (Abstract #3670)
      --  Preclinical Pharmacology and in vitro Characterization of PR-047, An
          Oral Inhibitor of the 20S Proteasome (Abstract #3671)
      Location: Moscone Center Hall A

About Proteolix

Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib (PR-171), the first in a new class of highly specific proteasome inhibitors, is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit http://www.proteolix.com.

     Contact information
     Investors:                      Media Inquiries:
     Matthew Ferguson                BCC Partners
     Chief Financial Officer         Karen L. Bergman or Michelle Corral
     650-266-2825                    650-575-1509 or 415-794-8662
     investors@proteolix.com

'/>"/>
SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 Today Stock-Callers.com have issued research ... Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences ... SSH ). These companies are part of the Healthcare sector, ... March 23 rd , 2017, with the NYSE Health Care ... care companies in the S&P 500 were down about 0.4% ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... care from the clinic, which opened March 22, 2017. , The team ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... financial planning, and related services to families and business owners across eastern Michigan, ... at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food ...
(Date:3/24/2017)... Diego, Calif. (PRWEB) , ... March 24, 2017 ... ... has raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on ... the instant demand for the product – with nearly 2,000 consumers (and counting) ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined the firm ... the firm, will concentrate her practice in elder law, Medicaid planning and applications, and ...
Breaking Medicine News(10 mins):